Visikol
1 known investors
Mattek develops in vitro life science technologies, including lab-grown 3D human epithelial tissue models, banks of primary human cells, and cell culture dishes and plates ("Cultureware") designed for cell growth and imaging. Its products serve researchers and scientists working in 2D culture and 3D tissue modeling.
Founders & leadership
MJ
Michael JohnsonCofounder30 Under 30 2017
Investors · 1
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.6M |
| National Science Foundation | Phase II | 2019 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $280K |
| National Science Foundation | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.5K |
| National Science Foundation | Phase I | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.